Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors

Mielczarek‐Palacz, Aleksandra; Sikora, Justyna; Kondera-Anasz, Zdzisława; Hauza, Grzegorz

doi:10.1016/j.humimm.2012.10.004

Cited by 16 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several studies demonstrating that key markers of platelet activation including soluble P-selectin [17][18][19], soluble CD40 ligand [19][20][21], platelet factor 4 [22], and platelet aggregation [23, 24] are increased in cancer patients compared to non-cancer control subjects. The role of platelet activation markers as predictive biomarkers of cancer-associated thrombosis has also been investigated (Table 1).…”

Section: Thrombocytosis Is a Biomarker Of Cancer-associated Thrombosismentioning

confidence: 99%

Platelets and Cancer-Associated Thrombosis

Connolly

Phipps

Francis

2014

Seminars in Oncology

View full text Add to dashboard Cite

Section: Thrombocytosis Is a Biomarker Of Cancer-associated Thrombosismentioning

confidence: 99%

Platelets and Cancer-Associated Thrombosis

Connolly

Phipps

Francis

2014

Seminars in Oncology

View full text Add to dashboard Cite

“…Also, a significantly increased soluble CD154 was detected in patients with lung cancer and more specifically those with squamous cancer [28]. Women suffering from ovarian tumors showed an elevated serum level of CD154 associated with an impaired apoptosis [29]. However, one should be careful while interpreting these findings as elevated concentrations of sCD154 in patients with different types of cancer might represent a relatively decreased level of the membrane-bound form of the molecule.…”

Section: Role Of Cd154 In the Pathogenesis Of Cancermentioning

confidence: 99%

Role of CD154 in cancer pathogenesis and immunotherapy

Hassan¹,

Stagg²,

Mourad³

2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…In addition to the enzymatic function of CD26, membranous CD26 also binds to its ligands, adenosine deaminase and caveolin‐1, to provide a costimulatory signal that enhances the activation of T cells . CD30 is a 120‐kD transmembrane glycoprotein that belongs to the tumor necrosis factor receptor superfamily, and is predominantly expressed on the surface of activated T cells, B cells and NK cells . Previously, it was shown that CD30 activation promotes the development of Th2 cells, and it was therefore considered to be an activation marker of Th2 cell populations.…”

Section: Introductionmentioning

confidence: 99%

Elevated levels of soluble CD26 and CD30 in multiple sclerosis

Basnyat

Natarajan

Vistbakka

et al. 2015

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Objective The activation of autoreactive T cells is a major event in the initiation of autoimmune responses in multiple sclerosis (MS). In addition to the T cell receptor stimulation, optimal activation of T cells requires various costimulatory molecules, such as CD26 and CD30, which has not been extensively studied in MS. Our aim was to explore whether the circulating levels of CD26 and CD30 in sera are associated with MS subtypes, inflammatory disease activity and disability in MS patients. Methods The study included 195 participants: 39 relapsing-remitting MS patients, 19 secondary-progressive MS patients, 19 clinically isolated syndrome patients, 58 controls for sCD26 analysis and 60 for sCD30 analysis. The levels of sCD26 and sCD30 in sera were analyzed using enzyme-linked immunosorbent assay, and the levels of interleukin-10, tumor necrosis factor-a and interferon-c were analyzed with the Luminex assay. Results We observed increased levels of sCD26 and sCD30 in relapsingremitting MS, secondary-progressive MS, and clinically isolated syndrome patients compared with the controls (P < 0.05). Furthermore, elevated levels of sCD30 were noticed in treated relapsing-remitting MS patients than in untreated patients (P = 0.016), and also in converted CIS patients than in unconverted patients (P = 0.009). Although sCD26 and sCD30 could not associate with clinical measures, such as the disability score or disease activity, the levels of sCD30 correlated positively with interleukin-10 levels (r = 0.583, P < 0.0001) and sCD26 levels (r = 0.262, P = 0.046) in MS patients. Conclusion The present results suggest that the elevated levels of sCD30 are associated with the regulatory immune responses predisposing to clinically stable phase of MS.

show abstract

Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors

Cited by 16 publications

References 26 publications

Platelets and Cancer-Associated Thrombosis

Platelets and Cancer-Associated Thrombosis

Role of CD154 in cancer pathogenesis and immunotherapy

Elevated levels of soluble CD26 and CD30 in multiple sclerosis

Contact Info

Product

Resources

About